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Gankyrin is an oncoprotein commonly overex-
pressed in most hepatocellular carcinomas.
Gankyrin interacts with S6 ATPase of the 19S
regulatory particle of the 26S proteasome and
enhances the degradation of the tumor sup-
pressors pRb and p53. Here, we report the
structure of gankyrin in complex with the C-
terminal domain of S6 ATPase. Almost all of
the seven ankyrin repeats of gankyrin interact,
through its concave region, with the C-terminal
domain of S6 ATPase. The intermolecular inter-
actions occur through the complementary
charged residues between gankyrin and S6
ATPase. Biochemical studies based on the
structure of the complex revealed that gankyrin
interacts with pRb in both the presence and ab-
sence of S6 ATPase; however, the E182 residue
in gankyrin is essential for the pRb interaction.
These results provide a structural basis for the
involvement of gankyrin in the pRb degradation
pathway, through its association with S6
ATPase of the 26S proteasome.
INTRODUCTION
Cell proliferation is controlled by the appropriate activities
and intracellular levels of tumor suppressors. The rapid
turnover of two major tumor suppressors, retinoblastoma
protein (pRb) and p53, is particularly critical for the regula-
tion of cell fate. pRb, a repressor of the transcription factor
E2F, is phosphorylated by the cyclin-dependent kinase
4/6 (CDK4/6)-cyclin D and CDK2-cyclin E complexes
(Connell-Crowley et al., 1997; Zarkowska and Mittnacht,
1997; Lundberg and Weinberg, 1998; Wallace and Ball,
2004) and is degraded by the ubiquitin-proteasome path-
way (Wang et al., 2001; Tedesco et al., 2002; Lim and Ele-
nitoba-Johnson, 2004; Uchida et al., 2005). The transcrip-
tion activator p53 is also degraded through ubiquitinationStructure 15, 179–1facilitated by the ubiquitin ligase activities of MDM2 and
p300 (Honda et al., 1997; Grossman et al., 2003). The de-
regulation of these two tumor suppressors leads to re-
duced fidelity of cell-cycle events, resulting in uncon-
trolled proliferation and cancer. Several mutations have
been detected in these tumor suppressors and ubiquitin
ligase components in carcinoma cells (Yandell et al.,
1989; Levine et al., 1991; Bond et al., 2004).
Degradation of the tumor suppressors pRb and p53 is
regulated by gankyrin (gann means cancer in Japanese),
an ankyrin repeat oncoprotein commonly overexpressed
in hepatocellular carcinomas (Higashitsuji et al., 2000,
2005a, 2005b). Gankyrin not only interacts with pRb, facil-
itating its phosphorylation and degradation (Higashitsuji
et al., 2000), but also associates with CDK4 to form a ter-
nary complex of gankyrin-CDK4-cyclin D (Dawson et al.,
2002; Li and Tsai, 2002). In addition, gankyrin binds to
MDM2 (E3 ubiquitin ligase) and augments its ubiquitinat-
ing activity against p53 (Higashitsuji et al., 2005a).
Gankyrin was initially identified as the p28 component
of the regulatory subunit of the cylindrical 26S protea-
some, which degrades ubiquitinated proteins (Hori et al.,
1998). Gankyrin was subsequently shown to interact
with the S6 ATPase subunit of the 19S regulatory particle
(Dawson et al., 2002). The 19S regulatory particle contains
six proteasomal ATPases, which belong to the AAA
(ATPases associated with diverse cellular activity) super-
family of ATPases. These proteasomal ATPases assemble
into a hexameric ring that directly touches the a ring of the
20S core particle. This hexameric ringmay function in sub-
strate unfolding and translocation. Although the tertiary
structures of the 20S core particles from different species
are known (Unno et al., 2002a, 2002b; Tomisugi et al.,
2000; Groll et al., 1997; Lowe et al., 1995), that of the
19S regulatory particle is not yet available.
To our knowledge, gankyrin is the first identified onco-
protein that interacts with a subunit of the 26S proteasome
and with tumor suppressors, and thus it may participate in
the regulation of cell proliferation by mediating the protea-
somal degradation of proteins, including tumor suppres-
sors. Based on previous reports, it can be hypothesized
that gankyrin is involved in the regulation of pRb activity89, February 2007 ª2007 Elsevier Ltd All rights reserved 179
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Crystal Structure of the Gankyrin ComplexFigure 1. Sequence Alignments of Gankyrin and the C-Terminal Domain of S6 ATPase, Used for Structure Analysis
(A) Sequence comparison of mouse (BAA36969) and human (BAA34594) gankyrin. The recognition motif of pRb, LxCxE, is underlined in blue
(aa 178–182).
(B) Sequence comparison of the C-terminal domain of S6 ATPase (P43686) with that of the other regulatory particle (RP) of human S4 ATPase
(AAA35484; 357–440), S6A ATPase (P17980; 358–439), S7 ATPase (P35998; 347–433), S8 ATPase (P62195; 321–406), and S10B ATPase
(P62333; 305–389), as well as with structurally homologous proteins, FtsH_HB8 (BAA96090; 327–394), and FtsH_E. coli (AAA97508; 326–400).
The a helices and b strands are indicated as helices and arrows, respectively. The alignment was produced by ClustalW (Thompson et al., 1994)
and was manually modified. The red characters indicate identical amino acids. The white characters on the red background indicate completely ho-
mologous amino acids among the respective groups. The blue and red triangles represent the basic and acidic residues, respectively, involved in
protein-protein interactions. The figure was generated by ESPript (Gouet et al., 1999).by interacting with CDK4 (phosphorylation), MDM2 (ubiq-
uitination), and S6 ATPase (proteasomal degradation).
Therefore, gankyrin is a potential candidate for developing
novel therapeutic drugs against liver cancers.
The native structures of human gankyrin and its yeast
homolog, Nas6p, have recently been reported (Krzywda
et al., 2004;Manjasetty et al., 2004; Yuan et al., 2004; Pad-
manabhan et al., 2004); however, it is still unclear how
gankyrin interacts with the aforementioned proteins and
regulates their respective functional roles. To understand
the molecular mechanism of gankyrin function, we deter-
mined the first, to our knowledge, crystal structure of gan-
kyrin in complex with the C-terminal domain of the S6
ATPase of the 26S proteasome. Gankyrin binds to the
S6 ATPase of the 26S proteasome through its concave re-
gion, composed of ankyrin repeats. The structure of the
complex revealed that all of the ankyrin repeats in gankyrin
are essential for the interaction with S6 ATPase, whereas
the C-terminal domain of S6 ATPase alone is sufficient for
association with its partner, gankyrin. Based on the crystal
structure and biochemical studies, we present the molec-180 Structure 15, 179–189, February 2007 ª2007 Elsevier Ltd Alular mechanism of the interactions between gankyrin, S6
ATPase, and pRb and propose a model for the involve-
ment of gankyrin in the pRb degradation pathway by the
26S proteasome.
RESULTS
Overall Structure of the Complex of Gankyrin with
the C-Terminal Domain of S6 ATPase
Themouse gankyrin protein (residues 1 to 231) (Figure 1A),
which shares 93% sequence identity with human gan-
kyrin, complexed with the C-terminal domain of human
S6 ATPase (S6-C, hereafter) (residues 337 to 418) (Fig-
ure 1B), was obtained by a coexpression method for
structure studies (see Experimental Procedures for
details).
The crystal structure of the His-WT gankyrin/S6-C com-
plex, which was crystallized in the P212121 space group
with one complexmolecule in an asymmetric unit, was de-
termined by the molecular replacement method, using the
human gankyrin structure (Krzywda et al., 2004) as thel rights reserved
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Crystal Structure of the Gankyrin ComplexFigure 2. Structure of the Gankyrin/S6-C Complex
(A) Ribbon representation of the mouse gankyrin/S6-C complex. Each ankyrin repeat of the gankyrin is indicated by ANK1–ANK7 (blue to red). The
S6-C tertiary structure is colored orange. The N and C termini of both molecules are indicated. Structural figures were generated with PyMOL (http://
pymol.sourceforge.net/).
(B) van der Waals surface representation of the protein complex. Gankyrin and S6-C are shown in pink and orange, respectively.search model. The initial solvent-flattened map and the in-
termediate maps obtained during the refinement cycle
were good enough to trace the chain of S6-C unambigu-
ously. The final complete structure of the protein complex,
refined at 2.3 A˚ resolution, gave R factor and R free values
of 16.9% and 23.8%, respectively (Figure 2 and Table 1).
In the final structure, three residues (residues 1–3) at the
N-terminal region of gankyrin and the C-terminal frag-
ment, 409–418, of S6-C were absent due to the poor elec-
tron density in these regions.
The tertiary structure of mouse gankyrin has an elon-
gated shape, with overall dimensions of 68 A˚ 3 22 A˚ 3
20 A˚, and comprises seven ankyrin repeats, ANK1–
ANK7 (Figure 2). The overall structure of mouse gankyrin
is very similar to that of human gankyrin (rms deviation
of 0.8 A˚) (see Figure S1A in the Supplemental Data avail-
able with this article online). Recent reports have provided
more details about the architecture of the gankyrin struc-
ture (Krzywda et al., 2004; Manjasetty et al., 2004; Yuan
et al., 2004) and that of its yeast homolog, Nas6p (Padma-
nabhan et al., 2004). Briefly, each ankyrin repeat contains
approximately 30 amino acid residues, which form a b-
hairpin followed by an HLH motif (Figure S1B). Although
all of the ankyrin repeats, ANK1–ANK7, adopt the tandem
ankyrin repeat fold (Sedgwick and Smerdon, 1999), the
ANK1 motif lacks a b strand, b1, and the ANK7 motif con-
tains a shorter helix, a13. The sequences of the ankyrin re-
peats ANK1 and ANK7, which flank the terminal ends, de-Structure 15, 179viate significantly from the ankyrin repeat consensus as
they are exposed to the solvent region. The antiparallel
a helices in each repeat stack together, forming a cup-
ped-hand-shaped structure. The surface created by the
b-hairpins and the a1 helices is concave, whereas that
formed by the a2 helices is convex.
The structure of S6-C forms a single folded domain with
a closely associated a-helical bundle, which is composed
of four a helices (a1, a2, a3, and a4) (Figure 2). The a1 and
a3 helices are nearly parallel to each other. The short helix,
a2, and the C-terminal helix, a4, are placed over the a1
and a3 helices, respectively. A long loop, comprising
about ten residues, connects the a1 and a2 helices (Fig-
ures 1B and 2).
Interaction between Gankyrin and S6 ATPase
Intriguingly, the structure of the gankyrin/S6-C complex
revealed that almost all of the ankyrin repeats of gankyrin
participate in S6-C interactions. The interface between
gankyrin and S6-C buries a solvent-accessible surface
area of about 2418 A˚2, which is significantly larger than
the observed average value of 1600 A˚2 for a protein-pro-
tein interaction surface (Jones and Thornton, 1996). A
sedimentation equilibrium analysis of the His-WT gan-
kyrin/S6-C complex provided a molecular mass value of
about 34 kDa (theoretical value: 37,465 Da) by fitting the
data in a single-species model mode (Figure 3A). In addi-
tion, the gel filtration elution patterns of the complex–189, February 2007 ª2007 Elsevier Ltd All rights reserved 181
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Crystal Structure of the Gankyrin Complexbetween gankyrin and the complete ATPase domain of S6
ATPase, comprising the N-terminal and C-terminal lobes
(residues 150 to 418; S6-A, hereafter), did not change in
the presence or absence of ATP (Figure 3B). This suggests
that the ATP molecule is unlikely to affect the interaction
between gankyrin and S6-A.
In gankyrin, the interaction occurs through its concave
region, comprising the b-hairpins and the a1 helices. S6-
C binds to gankyrin through the loops a1/a2, a2/a3, and
a3/a4, and the a2 and a4 helices. The a1/a2 and a3/a4
loops interact with the first four ankyrin repeats, ANK1–
ANK4, while the loop a2/a3 associates with the ankyrin re-
peats, ANK5–ANK6, of gankyrin. The structure of the com-
plex resembles a palm clasping a bundle. The a2 and a4
helices face inward, while the other two helices are ex-
posed to the solvent region.
An electrostatic surface potential analysis of the com-
plex clearly showed that the interaction occurs mainly via
polar interactions. In the interface region, threemajor com-
plementary surface potential patches were observed in
gankyrin andS6-C (Figures 4Aand4B). Thebindingoccurs
through their complementary surface regions: gankyrin
Table 1. Summary of Data Collection and Refinement
Statistics
Gankyrin/S6-C Complex
Data Collectiona
Source BL26B1, SPring-8
Wavelength (A˚) 1.0000
Space group P212121
Unit cell (A˚) a = 45.8, b = 67.9,
c = 107.8
Resolution (A˚) 20.0–2.3
Completeness (%) 96.5 (83.9)
I/s 14.0 (4.3)
Rmerge
b (%) 0.093 (26.9)
Refinement Statistics
No. complex molecules in a.u. 1
Resolution limit (A˚) 20.0–2.3
s cutoff 0
R factorc/Rfree
d (%) 16.9/23.8
No. protein residues 302
No. water molecules 285
Rms Deviations
Bond lengths (A˚) 0.011
Bond angles () 1.46
aNumbers in parentheses are values in the highest resolution
shell.
b Rmerge =
P jIobs <I>j=P<I> summed over all observa-
tions and reflections.
c Rcryst =
P jFobs  Fcalcj=
P
Fobs:
dRfree calculated with 5% of data omitted from refinement.182 Structure 15, 179–189, February 2007 ª2007 Elsevier Ltdpossesses one positively (ANK2–ANK4) and two nega-
tively (ANK2–ANK3 and ANK6–ANK7) charged patches
(Figure 4A), whereas S6-C has one negatively (a1/a2
loop and thea2helix) and twopositively (a1 anda4helices)
charged regions (Figure 4B). An analysis of the intermolec-
ular interactions between gankyrin and S6-C revealed the
existence of about 25 electrostatic interactions between
them (Table S1). Among the intermolecular interactions,
there are six potential universal salt links (Figure 4C).
Asp362 and Lys397 of S6-C each make two salt bridges
with Asn105/Arg145 (ANK4/ANK5) and Asp39/Asp71
(ANK2/ANK3), respectively, in gankyrin. Similarly, Glu357
and Arg342 of S6-C form salt bridges with the Arg41 and
Glu182 residues, respectively, in gankyrin. Intriguingly,
the residue Glu182 (ANK6), which creates a potential salt
link as well as a hydrogen bond interaction through its car-
bonyl group with Arg342 of S6-C, is a part of the LxCxE
motif, which participates in pRb binding (Higashitsuji
et al., 2000). In the interface, only one potential hydropho-
bic interaction was found, near the Leu395 residue of S6-
C. This residue binds in the hydrophobic pocket created
by Val5, Tyr15, Trp46, and the aliphatic moiety of Arg41
of gankyrin, and Ile393 and the aliphatic moiety of
Arg391 of S6-C. Among the buried water molecules in
the binding interface, five potentially buried water mole-
cules form bridges between the gankyrin and S6-C mole-
cules through hydrogen-bond interactions (Table S1).
Effects of Gankyrin and S6-C Mutations
on Complex Formation
To determine which residues in S6-C are responsible for
the gankyrin interaction and vice versa, we assessed the
complex formation between gankyrin and S6-C mutants
in E. coli lysates. The expression of the wild-type S6-C
protein alone (i.e., expression in the absence of gankyrin)
yielded only the aggregated form of S6-C (data not
shown). On the other hand, the soluble S6-C protein was
detected when it was coexpressed with gankyrin (Fig-
ure 4D, lane 1), indicating that complex formation with
gankyrin is essential for the solubility of S6-C. We thus
postulated that the S6-C protein would aggregate even
when coexpressed with gankyrin, if the mutation critically
affected the complex formation with gankyrin. We mu-
tated the residues R342A, R338A/R342A, R338A/R339A/
R342A, E356A/E357A, D359A/D362A, and K397E in
S6-C and the residues R41A, K116A, D39A/D71, R41A/
K116A, and E182A in gankyrin. As shown in Figure 4D, ex-
pression of the soluble S6-C was drastically reduced, ex-
cept for the K397E and R342Amutants (Figure 4D, lanes 2
and 5), assuming that the mutations do not have a detri-
mental effect on the protein itself. The amount of S6-C
binding to gankyrin was decreased with the R338A and
R339A mutants of S6-C, as compared with the wild-type
gankyrin-S6-C complex. In addition, coexpression of the
gankyrin mutants R41A and R41A/K116A with the wild-
type S6-C reduced the solubility of S6-C (Figure 4E, lanes
2 and 5). These results suggest that R41 in gankyrin is one
of the potential residues involved in binding to S6-C. Strik-
ingly, the E182A mutant in gankyrin, a part of the LxCxEAll rights reserved
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Crystal Structure of the Gankyrin ComplexFigure 3. Protein Characterization of the
Gankyrin/S6-C Complex
(A) Sedimentation equilibrium analysis of the
His-WT gankyrin/S6-C complex. Absorbance
distributions are shown for the sedimentation
of the protein complex (0.5 mg ml1) at 5C,
at rotor speeds of 12,000 rpm (squares),
15,000 rpm (triangles), and 20,000 rpm (cir-
cles). Concentration profiles of the samples
were monitored by the absorbance at 280
nm. All of the data were globally fit to a single
species component model. The upper panel
shows the residual difference between the ex-
perimental and fitted values by its standard de-
viation for the speed of 20,000 rpm (data not
shown for the other two speeds, for clarity).
(B) Elution profiles of His-WT gankyrin/S6-A
complex (with or without 2 mM ATP) on
a Superdex200 HiLoad 16/60 column (Amer-
sham Biosciences). The chromatography
was conducted in 20 mM Tris-HCl, 150 mM
NaCl, 2 mM DTT (pH 8.0), at a flow rate of
0.5 ml min1, and the elution profile was mon-
itored by the absorbance at 280 nm. The
elution patterns of the ATP-free conditions
and the 2 mM ATP conditions were quite
similar.motif, did not affect the interaction between these two
proteins (Figure 4E, lane 6).
Binding Affinity of pRb toGankyrin in the Presence or
Absence of S6 ATPase
Previous studies suggested that the pRb-recognition mo-
tif, LxCxE, in gankyrin (LACDE; residues 178 to 182) plays
an important role in the pRb interaction (Higashitsuji et al.,
2000). In our structure of the complex, the Glu182 residue
makes a salt link with Arg342 of S6-C. To determine
whether this residue in gankyrin is essential for the pRb in-
teraction, we performed a GST pull-down assay to moni-
tor the ability of pRb to interact with the wild-type (WT) or
mutant (E182A) gankyrin, with or without S6-C. A similar
experiment was also carried out for the complete ATPase
domain of S6 ATPase, S6-A.
The amount of gankyrin interacting with pRb was higher
in WT-gankyrin than in gankyrin (E182A) (Figure 5A). The
same tendency was observed when gankyrin was in com-Structure 15, 17plex with S6-C or S6-A, i.e., the gankyrin levels that were
pulled downwith pRbwere higher withWT-gankyrin/S6-C
or S6-A than with gankyrin (E182A)/S6-C or S6-A (Fig-
ure 5B). These results indicated that pRb interacted with
gankyrin, regardless of the presence or absence of S6
ATPase, and that the Glu182 residue of gankyrin seems
to be essential for the pRb interaction. On the other
hand, the levels of S6 ATPase (S6-A or S6-C) pulled
down with GST-pRb showed a different pattern as com-
pared with that of gankyrin (Figure 5B). It may be that
the complete ATPase domain of S6 ATPase is necessary
for stable complex formation with gankyrin in solution.
However, further structural studies are needed to under-
stand how gankyrin, pRb, and S6 ATPase are arranged
in a ternary complex. The polyclonal antibody against S6
ATPase used in this study more sensitively detected S6-
A than S6-C, probably due to the length of the protein, re-
sulting in stronger band intensities of S6-A than S6-C, as
in Figure 5B.9–189, February 2007 ª2007 Elsevier Ltd All rights reserved 183
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Crystal Structure of the Gankyrin ComplexFigure 4. The Interacting Region between Gankyrin and S6-C
(A and B) A surface potential representation of gankyrin (A) and S6-C (B). The complementary surface patches responsible for complex formation are
shown by circles (labeled as A, B, and C in gankyrin, and as A0, B0, and C0 in S6-C, respectively). Red, blue, and white represent acidic, basic, and
neutral, respectively.
(C) A cartoon representation of the interacting region of the complex. Potential interacting residues are shown by sticks. Buried water molecules are
not shown for clarity. The hydrogen bonds formed from the side chains are indicated by dashed lines. The LxCxE motif in gankyrin is shown in gray.
Other coloring for the cartoon diagram is the same as in Figure 2A.
(D) Identification of the S6-C residues responsible for the complex formation with gankyrin. The bacterial lysates, in which the wild-type gankyrin and
the indicated S6-C mutant were coexpressed, were analyzed by SDS-PAGE. The effects of point mutations in S6-C upon complex formation with
gankyrin were evaluated by the amounts of the soluble S6-C protein. The S6-C mutants E356A/E357A (lane 3), D359A/D362A (lane 4), and
R338A/R339A/R342A (lane 7) showed a substantial reduction in gankyrin binding, as compared to wild-type gankyrin/S6-C (lane 1).
(E) Identification of the gankyrin residues responsible for the complex formation with S6-C. The assay was done as essentially as in (D). The gankyrin
mutants R41A (lane 2) and R41A/K116A (lane 5) significantly disrupt the interaction in the complex, as compared to wild-type gankyrin/S6C (lane 1).
The respective mutation(s) are indicated at the top.184 Structure 15, 179–189, February 2007 ª2007 Elsevier Ltd All rights reserved
Structure
Crystal Structure of the Gankyrin ComplexDISCUSSION
We have described the first, to our knowledge, crystal
structure of the gankyrin complex with the C-terminal do-
main of S6 ATPase (S6-C) of the 19S regulatory particle.
As revealed by the present crystal structure of the
complex, gankyrin can be a subunit of the RC of the pro-
teasome, through its association with the C-terminal do-
main of S6 ATPase (Hori et al., 1998; Dawson et al.,
2002), and it is also capable of binding to the free, nonpro-
teasomal S6 ATPase, in a manner similar to that of the
HEC protein (highly expressed in cancer cells) binding to
free S7 ATPase. The HEC protein controls the degradation
of mitotic cyclin B in vitro, by modulating the ATPase ac-
tivity of free S7 ATPase (Chen et al., 1997). Hence, these
previous reports suggested that gankyrin might also be in-
volved in controlling protein degradation, by associating
Figure 5. Gankyrin Interacts with pRb in the Presence and
Absence of S6 ATPase
(A) pRb-dependent pull-down of gankyrin. His-tagged gankyrin pro-
teins (left, the wild-type; right, the E182A mutant, in which the LxCxE
pRb binding motif was altered to LxCxA) were pulled down with
GST-pRb (residues 372–288) or GST and were visualized by western
blotting with an anti His-tag antibody.
(B) S6 ATPase-independent pull-down of gankyrin by pRb. The His-
tagged gankyrin/S6-C and His-tagged gankyrin/S6-A proteins (wild-
type gankyrin or the E182A mutant) were pulled down with GST-pRb
(residues 372–288) or GST. The polyclonal antibody against S6
ATPase used in the experiment had higher sensitivity to S6-A than to
S6-C, probably due to the protein size. Note that pRb interacts with
gankyrin and the gankyrin mutant (E182A) in the same pattern, regard-
less of the presence of the S6 ATPase.Structure 15, 179–with the nonproteasomal S6 ATPase protein. Another in-
teresting feature revealed by our structural and biochem-
ical studies is that ATP is not required for the interaction
between S6 ATPase and gankyrin, at least at the nonpro-
teasome level.
As none of the structures of the six ATPases of the 19S
regulatory particles is known, we performed aDALI search
(Holm and Sander, 1999), using the S6-C domain struc-
ture, to obtain the structurally homologous proteins avail-
able in the PDB. This search revealed that the S6-C struc-
ture closely resembles the structure of the AAA ATPase
family of the C-terminal domain of FtsH, from Thermus
thermophilus HB8 and Escherichia coli (Niwa et al.,
2002; Krzywda et al., 2002), with Z score values of 12.5
and 13.1, respectively. Superpositioning the structures
corresponding to these two domains suggested that the
two structures are essentially quite similar (rms deviations
of 1.3 and 1.4 A˚ over 74 main chain residues), despite their
low sequence similarity (25%) (Figure 1B and Figure S2).
Thus, the overall S6 ATPase structure might be very sim-
ilar to that of FtsH and might also be maintained among
the AAA ATPase family proteins. Since the C-terminal
domain of S6 ATPase adopts a structure nearly identical
to that of the FtsH counterpart, we modeled the gankyrin
complex with the complete ATPase domain of S6
ATPase (aa 269: 150–418), using the FtsH structure from
Thermus thermophilus HB8 (Niwa et al., 2002) (Figure 6).
In this model, moderate intermolecular interactions were
Figure 6. Model of Gankyrin in Complex with the Complete
ATPase Domain of S6 ATPase
The structure of the gankyrin/S6-C complex is superposed between
the S6-C domain and the C-terminal domain of the FtsH_E.coli struc-
ture for the Ca-atoms. The coloring code for the gankyrin/S6-C com-
plex is the same as in Figure 2A, and the FtsH_E. coli structure is
shown in yellow.189, February 2007 ª2007 Elsevier Ltd All rights reserved 185
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Crystal Structure of the Gankyrin Complexobserved between a loop in the N-terminal domain of S6
ATPase and the ankyrin repeats, ANK6–ANK7, of gan-
kyrin, in addition to major interactions with the C-terminal
domain of S6 ATPase (Figure 6). A comparison of the
structures between the gankyrin/S6-C complex and na-
tive gankyrin (Krzywda et al., 2004) indicated that gankyrin
slightly bends to interact with the surface of S6-C (Fig-
ure S1). The structure of the yeast homolog (Padmanab-
han et al., 2004), Nas6p, also shows similar behavior, as
compared with that of the gankyrin in the gankyrin/S6-C
complex (data not shown). Therefore, we speculate that
the gankyrin structure (and those of its homologs) is quite
rigid and does not change much when it binds to S6
ATPase.
The complex formation is stabilized by complementary
surface-charged residues residing at the buried interface.
From the present mutagenesis study, we demonstrated
that alanine substitutions in either the negatively charged
region of the a1/a2 loop and the a2 helix or the positively
charged region of the a1 helix in S6-C resulted in a
dramatic loss of the binding affinity with gankyrin (Fig-
ure 4D, lanes 3, 4, and 7). In addition, R41 in gankyrin is
indeed one of the essential residues for binding to S6-C
(Figure 4E, lanes 2 and 5). Therefore, these results suggest
that complementary ionic interactions from these surface
patches are necessary to form a strong complex between
gankyrin and S6 ATPase.
Our data revealed that the binding between gankyrin
and S6 ATPase is highly selective. As expected, the C-ter-
minal regions of the ATPase domains of all six ATPases
exhibit less sequence similarity (Figure 1B) as compared
to the N-terminal regions of the ATPase domains (data
not shown), which all share the same catalytic function.
Nevertheless, the residues in the gankyrin interacting re-
gions have highly diverged among the ATPase subunits.
For example, R338 in a1 of S6 ATPase is positively
charged, while the corresponding residues in the other
26S proteasomal ATPases have been replaced with either
negatively charged or hydrophobic residues. Thus, the
above findings indicate that the gankyrin protein specifi-
cally interacts with S6 ATPase, but not with other subunits
of the 19S regulatory particle, in agreement with recent
biochemical studies confirming that gankyrin specifically
interacts with the S6 ATPase of the 26S proteasome
(Dawson et al., 2002).
Gankyrin directly associates with CDK4 and counter-
acts the inhibitory function of p16INK4A (Li and Tsai,
2002). The p16INK4A protein, which possesses four ankyrin
repeats, inhibits pRb phosphorylation by interacting with
CDK4/6. In the structure of the p16INK4A/CDK6 complex,
the concave region of the first three ankyrin repeats of
p16INK4A is mainly involved in intermolecular interactions
with CDK6 (Russo et al., 1998). Recent in vitro studies
showed that the first four ankyrin repeats of gankyrin are
sufficient for the CDK4 interaction (Li and Tsai, 2002)
and also suggested that the bindingmodemight be similar
to that of p16INK4A, as revealed by a competition assay
(Yuan et al., 2004). Although gankyrin binds to CDK4,
our results suggest that it is unlikely to interact with186 Structure 15, 179–189, February 2007 ª2007 Elsevier Ltd AlCDK4 and S6 ATPase simultaneously, as gankyrin uses
the same region to interact with CDK4 and S6 ATPase.
A recent study mentioned that the interaction between
gankyrin and endogenous CDK4 or S6 ATPase was
observed onlywhen the cells had been treatedwith a strin-
gent lysis buffer, leading to the conclusion that the com-
ponents of the gankyrin-containing complex may have
been compartmentalized or associated with lipid mem-
branes in living cells (Dawson et al., 2002). Such a mecha-
nism in living cells may play an important role in determin-
ing the correct partner protein(s) of gankyrin at the
appropriate time.
Several viral oncoproteins, as well as at least 84 cellular
proteins, reportedly interact with pRb, and at least 19 of
themhave the LxCxEbindingmotif (Dick et al., 2000; Singh
et al., 2005). The LxCxE motif in gankyrin possesses an a-
helical conformation (Figures 1A and 4C), in contrast to the
b strand LxCxE peptide in complex with pRb (Lee et al.,
2002). This motif is insufficiently exposed to the solvent re-
gion, except for Glu182, which lies at the tip of the helix. As
discussed recently, based on the native structures of gan-
kyrin and its homolog, Nas6p (Krzywda et al., 2004; Pad-
manabhan et al., 2004), this motif probably does not inter-
act with pRb, at least not in the same manner as that
observed with the HPV E7 peptide. Glu182 is surrounded
by Arg338, Arg339, and Arg342 of S6-C and Arg184 of
gankyrin. Although Glu182 forms a salt link with Arg342,
which lies in one of the four binding sites of S6-C, surpris-
ingly, it did not affect the stability of the interactionbetween
gankyrin and S6-C (Figure 4D, lane 5, and Figure 4E, lane
6). On the other hand, the level of binding was drastically
reduced between pRb and gankyrin (E182A) (Figure 5A),
the gankyrin (E182A)/S6-C complex, and the gankyrin
(E182A)/S6-A complex (Figure 5B), indicating that the
Glu182 residue in gankyrin is indeed essential for the inter-
action with pRb, supporting the previous observations (Hi-
gashitsuji et al., 2000; Li and Tsai, 2002).
In the present study, we demonstrated that the binding
affinity between pRb and gankyrin was not influenced by
the presence or absence of S6 ATPase (Figure 5). We
also confirmed that a significant amount of S6-A copreci-
pitated with GST-pRb and His-gankyrin. Since we were
unable to perform the pull-down assay by using GST-
pRb against S6-A or S6-C as controls, because the apo
forms of S6-A and S6-C are insoluble, the possible com-
plex formation by pRb, gankyrin, and S6 ATPase has yet
to be clarified. From a structural viewpoint, we found
strong binding between gankyrin and S6 ATPase, while
the binding between gankyrin and pRb seemed to depend
on the LxCxE motif of gankyrin, as mentioned above.
Therefore, it is possible that a replacement between pRb
and S6 ATPase can occur on gankyrin to some extent. A
previous in vivo study demonstrated that the overexpres-
sion of gankyrin was correlated with the degradation of
pRb (Higashitsuji et al., 2000). Taken together with our re-
sults, we can hypothesize that gankyrin functions to carry
pRb, which is phosphorylated by CDK4/6, to the 26S pro-
teasome site. Then, gankyrin binds to S6 ATPase and sub-
sequently releases pRb for its degradation at the 26Sl rights reserved
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CDK4/6, pRb, and the 26S proteasome are essential for
clarifying the proposed hypothesis.
In summary, the structure of the gankyrin/S6-C com-
plex provides further insights into the relationship between
gankyrin and the 26S proteasome and the possible func-
tion of gankyrin in protein degradation. In addition, it is
likely that S6 ATPase and pRb have different binding affin-
ities to gankyrin, which may play an important role in the
replacement of these proteins on gankyrin at the 26S pro-
teasome, when gankyrin carries pRb to the 26S protea-
some for degradation. However, the structure of the gan-
kyrin/pRb complex is required to further understand the
molecular mechanism of pRb degradation at the protea-
some level.
EXPERIMENTAL PROCEDURES
Plasmids
His-Wild-Type Gankyrin, His-WT Gankyrin/S6-C,
and His-WT Gankyrin/S6-A
The open reading frame of the gene encoding mouse gankyrin was
subcloned into the pET19b (Novagen) vector at the NdeI and XhoI re-
striction sites, to obtain the pET19b-gankyrin expression plasmid. The
cDNA of mouse gankyrin was also subcloned into cassette1 of pET-
Duet1 (Novagen) at the BamHI and NotI restriction sites, to yield the
pETDuet1-gankyrin expression plasmid. Additionally, the cDNAs en-
coding the C-terminal region of human S6 ATPase (aa 337–418, S6-
C) and the complete ATPase domain of human S6 ATPase (S6-A: aa
150–418) were subcloned into the second cassette of pETDuet1 at
the NdeI and XhoI restriction sites, in order to obtain the pETDuet1-
gankyrin/S6-C and pETDuet1-gankyrin/S6-A expression plasmids, re-
spectively. The pET19b-gankyrin plasmid was used for the expression
of His-wild-type (WT) gankyrin, while the pETDuet1-gankyrin/S6-C
and pETDuet1-gankyrin/S6-A plasmids were used for the expression
of the His-WT gankyrin/S6-C complex and the His-WT gankyrin/
S6-A complex, respectively.
GST-pRb
The gene encoding human pRb, from amino acids 372 to 788, was
subcloned in the pGEX-6p-1 vector (Amersham Biosciences) at the
BamHI and XhoI restriction sites, in order to express GST-pRb (aa
372–788).
Protein Expression and Purification
Escherichia coli, Rosetta(DE3) (Novagen), was used for the expression
of the proteins mentioned above. For all of the expressed proteins, the
bacteria were grown at 37C in LBmedium, containing 50 mgml1 am-
picillin and 34 mgml1 chloramphenicol, until theOD600 reached a value
of 0.5. Protein expression was then induced by the addition of IPTG to
a final concentration of 0.4 mM. After 6 hr of culture at 37C for His-WT
gankyrin, His-WT gankyrin/S6-C, and His-WT gankyrin/S6-A, or after
20 hr of culture at 15C for GST-pRb, the cells were harvested by cen-
trifugation at 9,600 3 g for 5 min and resuspended in 50 ml of buffer,
containing 20 mM Tris-HCl (pH 8.0) and 500 mM KCl. The cells were
then homogenized with a sonicator (TOMY), and the homogenate
was centrifuged at 20,0003 g for 1 hr. The resultant supernatants con-
taining His-WT gankyrin, His-WT gankyrin/S6-C, andHis-WT gankyrin/
S6-A were then applied to a HiTrap Chelating HP column (Amersham
Biosciences), and the target proteins were eluted with buffer contain-
ing 0.5 M imidazole. For further purification of the target proteins, the
proteins were processed on a HiTrapQ anion exchange column (Amer-
sham Biosciences), which was eluted by a linear gradient of NaCl
from 0 M to 1.0 M. The fractions containing the target proteins were
pooled and fractionated on a HiLoad 16/60 Superdex 200 gel-filtration
column (Amersham Biosciences). The pooled His-WT gankyrin, His-Structure 15, 179–WT gankyrin/S6-C, and His-WT gankyrin/S6-A proteins were concen-
trated to 6 mgml1, 7 mgml1, and 1 mgml1, respectively, with Cen-
triprep YM-10 filters (Millipore). For GST-tagged pRb, a GSTrap col-
umn (Amersham Biosciences) was used for the preliminary affinity
purification.
Crystallization and Data Collection
Crystallization of His-WT gankyrin/S6-Cwas carried out at 20C by the
hanging-drop vapor diffusion method. Small needle-like crystals of the
complex were obtained under conditions 9 and 41 of the crystal screen
I kit (Hampton Research). In order to obtain larger single crystals for
X-ray analysis, the crystallization conditions were further optimized.
The best crystals were obtained from 23%PEG6000 (pH 7.5), contain-
ing 0.2 M MgSO4, at 20
C. An X-ray diffraction data set was collected
at the beamline BL26B1 (SPring-8, Hyogo, Japan). The data were inte-
grated and scaled with HKL2000 (Otwinowski and Minor, 1997). The
results of the data reduction statistics are summarized in Table 1.
Structure Determination and Refinement
The structure of the gankyrin/S6-C complex was determined by the
molecular replacement method, employing the human gankyrin struc-
ture as a search model, with the program Molrep from the CCP4 suite
(CCP4, 1994). It gave a distinct peak with an R factor and a correlation
coefficient of 49.6% and 42.4%, respectively, for the resolution be-
tween 20 A˚ and 4 A˚. The model was refined with CNS (Brunger et al.,
1998), and several rounds of manual fitting and refitting were carried
out by using the programO (Jones et al., 1991), with careful inspection
of the 2Fo  Fc, Fo  Fc, and omit electron density maps. The refined
current model consists of 302 residues and 285 water molecules,
with a final Rwork and an Rfree of 16.9% and 23.8%, respectively, at
2.3 A˚ resolution. The stereochemistry of the gankyrin/S6-C complex
structure is excellent, as checked with PROCHECK (Laskowski
et al., 1993). The refinement statistics are summarized in Table 1.
Sedimentation Equilibrium Analysis
Sedimentation equilibriumwas performed on anOptima XL-I analytical
ultracentrifuge (Beckman) in an eight-hole An50Ti rotor at 5C, with
equilibrium six-channel centerpieces and quartz windows. Concentra-
tion profiles of the samples were monitored by the absorbance at
280 nm. The sedimentation equilibrium experiments for the His-WT
gankyrin/S6-C complex at a concentration of 0.5 mgml1, and at rotor
speeds of 12,000, 15,000, and 20,000 rpm, were carried out. Scans
were recorded after 12 hr, 14 hr, and 16 hr at each speed. Data
were analyzed by the Beckman analysis software, based on the
Origin 6.0 package (Microcal). The data analysis in a single species
model mode yielded a molecular mass of 34.8 Da (theoretical value:
37,465 Da) and a variance of 3.63E5. A partial specific volume of
0.738 cm3 g1 was used, and the background absorbance was cor-
rected empirically by allowing the baseline to float during the fitting
calculation.
Gel-Filtration Analysis
Gel-filtration experiments were performed with a Superdex200 HiLoad
16/60 column (Amersham Biosciences). The His-WT gankyrin/S6-A
complex was preincubated with 2 mM ATP on ice for at least 2 hr.
The chromatography was conducted in 20 mM Tris-HCl (pH 8.0),
150 mM NaCl, and 2 mM DTT at a flow rate of 0.5 ml min1, and the
elution profile was monitored by the absorbance at 280 nm.
Mutations in S6-C and Gankyrin
The site-directed mutagenesis of the S6-C and gankyrin cDNAs was
conducted in the previously constructed pET19b-gankyrin and
pETDuet1-gankyrin/S6-C plasmids. Several mutants of His-gankyrin/
S6-C, R342A, R338A/R342A, R338A/R339A/R342A, E356A/E357A,
D359A/D362A, and Lys397E in S6-C, as well as R41A, K116A,
D39A/D71A, R41A/K116A, and E182A in gankyrin, were directly intro-
duced into the plasmid by PCR reactions with a QuikChangeMutagen-
esis Kit (Stratagene). The plasmids were expressed in E. coli Rosetta189, February 2007 ª2007 Elsevier Ltd All rights reserved 187
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Crystal Structure of the Gankyrin Complex(DE3), and the cells were homogenized by sonication. The soluble frac-
tion of the E. coli lysate was separated by centrifugation at 15,0003 g
for 60 min, and the expression of the proteins were confirmed by SDS-
PAGE. In addition, the gankyrin (E182A) cDNA was subcloned in pET-
Duet1 and pETDuet1-S6-A, in order to obtain pETDuet1-gankyrin
(E182A) and pETDuet1-gankyrin (E182A)/S6-A, respectively. The plas-
mid was expressed in E. coli Rosetta (DE3), and the expressed pro-
teins were purified by chromatography on a HiTrap Chelating HP col-
umn and a HiLoad 16/60 Superdex 75 gel-filtration column (Amersham
Biosciences). The purity of the proteins was confirmed by SDS-PAGE.
GST Pull-Down Assay
A 100 pmol aliquot of GST-pRb (372–788) was added to 1 nmol each of
(1) His-WT gankyrin, (2) His-gankyrin (E182A), (3) His-WT gankyrin/S6-
C, (4) His-gankyrin (E182A)/S6-C, (5) His-WT gankyrin/S6-A, and (6)
His-gankyrin (E182A)/S6-A. As negative controls, 100 pmol of GST
was added to 1 nmol of protein samples of (1)–(6). The total volume
of each reaction solutionwas adjusted to 100 ml with the reaction buffer
(20 mM Tris-HCl, 150 mM NaCl, 2 mM DTT [pH 8.0]). The protein mix-
tures were then incubated at 4C for 1 hr. Following the incubation,
a 50 ml aliquot (resin volume) of Glutathione-Sepharose HP resin
(Amersham Biosciences) was added to each tube, and the protein-
resin mixture was incubated at 4C with mild agitation for 1 hr. After
the resin was washed five times with 1 ml of the reaction buffer, the
bound proteins were eluted with 40 ml of an elution buffer (50 mM
Tris-HCl, 150 mM NaCl, 2 mM DTT, 10 mM glutathione [pH 7.7]), by
vigorous mixing for 30 min at room temperature. The eluted proteins,
as well as 2 pmol protein samples of (1)–(6) as inputs, were separated
by SDS-PAGE. The His-gankyrin (either wild-type or mutant) and S6
ATPase (either S6-C and S6-A) that coprecipitated with GST-pRb
was detected by western blotting with antibodies against the His-tag
(Cell Signaling, #27E8) and against S6 ATPase (BIOMOL, #PW8175),
followed by a horseradish peroxidase-conjugated goat antibodies
against mouse IgG and rabbit IgG (Amersham Biosciences), respec-
tively. The band detection was accomplished with the Chemi Lumi-
One L western blotting detection system (Nacalai Tesque).
Supplemental Data
Supplemental Data include one table and two figures and are available
at http://www.structure.org/cgi/content/full/15/2/179/DC1/.
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